Y Intercept Hong Kong Ltd Makes New Investment in Bausch + Lomb Co. (NYSE:BLCO)

Y Intercept Hong Kong Ltd acquired a new position in shares of Bausch + Lomb Co. (NYSE:BLCO - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 28,791 shares of the company's stock, valued at approximately $555,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. XTX Topco Ltd acquired a new stake in Bausch + Lomb in the third quarter valued at about $309,000. State Street Corp lifted its holdings in shares of Bausch + Lomb by 5.6% in the third quarter. State Street Corp now owns 28,450 shares of the company's stock worth $549,000 after acquiring an additional 1,510 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Bausch + Lomb in the 3rd quarter valued at approximately $526,000. Point72 DIFC Ltd bought a new stake in shares of Bausch + Lomb during the 3rd quarter valued at approximately $4,331,000. Finally, Polar Asset Management Partners Inc. acquired a new position in Bausch + Lomb during the 3rd quarter worth approximately $289,000. Institutional investors own 11.07% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Needham & Company LLC restated a "hold" rating on shares of Bausch + Lomb in a research report on Thursday, October 31st. Wells Fargo & Company raised their price objective on Bausch + Lomb from $23.00 to $26.00 and gave the company an "overweight" rating in a report on Thursday, October 31st. Bank of America reaffirmed an "underperform" rating and issued a $18.00 target price on shares of Bausch + Lomb in a report on Thursday. HC Wainwright reissued a "buy" rating and set a $23.00 price target on shares of Bausch + Lomb in a research note on Thursday. Finally, Morgan Stanley cut Bausch + Lomb from an "overweight" rating to an "equal weight" rating and set a $19.00 price target on the stock. in a report on Monday, December 2nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Bausch + Lomb has a consensus rating of "Hold" and a consensus price target of $20.58.

Bausch + Lomb Trading Down 0.3 %

NYSE:BLCO traded down $0.05 on Monday, reaching $18.55. 447,619 shares of the stock traded hands, compared to its average volume of 561,534. The firm has a market capitalization of $6.53 billion, a price-to-earnings ratio of -17.67, a price-to-earnings-growth ratio of 1.74 and a beta of 0.43. Bausch + Lomb Co. has a 1-year low of $13.16 and a 1-year high of $21.69. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. The company's 50 day moving average is $19.87 and its 200-day moving average is $17.55.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.01. The company had revenue of $1.20 billion during the quarter, compared to analysts' expectations of $1.17 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. Bausch + Lomb's revenue for the quarter was up 18.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.22 earnings per share. Equities research analysts anticipate that Bausch + Lomb Co. will post 0.6 EPS for the current fiscal year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.